Robyn Karnauskas’s biotech blue skies have turned dark and stormy.
During the biotech boom-boom years, Citi’s large-cap biotech analyst earned a reputation for being eternally sunny. To Karnauskas, every drug was a blockbuster. Buy ratings were bountiful. Price targets moved in only one direction: up.
Wow – Porges writes. “We don’t see this uncertainty lifting in 2018, and possibly not ever.” Should I keep my subscription?
Comments are closed.